Format

Send to:

Choose Destination
See comment in PubMed Commons below
BMC Cancer. 2010 Jul 30;10:398. doi: 10.1186/1471-2407-10-398.

Adjuvant radiotherapy and chemotherapy in breast cancer: 30 year follow-up of survival.

Author information

  • 1University Department of Surgery, Faculty of Medicine, University of Glasgow, Glasgow, UK, G12 8RZ.

Abstract

BACKGROUND:

The long term outcome (more than 15 years) of adjuvant treatment in patients with primary operable breast cancer has rarely been examined.

METHODS:

A randomised clinical trial of radiotherapy, chemotherapy (28 day cycles of cyclophosphamide, methotrexate and 5-fluorouracil) or both on women with primary operable breast cancer (n = 322) was followed-up for a median of 27 years.

RESULTS:

260 (81%) patients died, 204 (78%) from breast cancer. Cancer specific survival (SE) at 10 years, 20 years and 30 years was 41 (3)%, 34 (3)% and 33 (3)% respectively. Presence of more than 3 involved lymph nodes increased cancer-specific mortality (HR 1.88, 95% CI 1.34-2.63) after adjustment for age, socio-economic deprivation and adjuvant treatment. Both age (HR 1.63, 95% CI 1.19-2.22) and involved lymph nodes (HR 1.59, 95% CI 1.17-2.14) were significant predictors of all-cause mortality after adjustment for other factors. There was no significant difference in all-cause or cancer-specific survival between patients in each of the 3 treatment arms.

CONCLUSIONS:

The present study highlights the long term impact of node positive disease but does not indicate that any regimen was associated with significantly better long-term survival.

PMID:
20673353
[PubMed - indexed for MEDLINE]
PMCID:
PMC2918580
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for BioMed Central Icon for PubMed Central
    Loading ...
    Write to the Help Desk